Nuwellis Inc.

Company Overview

Business Model: Nuwellis, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing medical devices for ultrafiltration therapy. Its primary product is the Aquadex System, which includes the Aquadex FlexFlow and Aquadex SmartFlow systems. These systems are indicated for temporary or extended use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. Revenue is primarily generated from the sale of disposable blood filters and catheters used with the Aquadex System consoles.

Market Position: The Aquadex System is positioned as a safe, predictable, and effective therapy for fluid overload, clinically proven to remove excess fluid (salt and water) from patients who have failed diuretic therapy. A key differentiator is that, unlike other ultrafiltration methods typically requiring a nephrologist, the Aquadex System can be prescribed by any physician and administered by a trained healthcare provider. The company estimates it has treated over 30,000 patients since reintroducing the system to the U.S. market in 2016. Nuwellis, Inc. states there are no direct competitors for the Aquadex System in heart failure or critical care in the United States, other than diuretics.

Recent Strategic Developments:

• Clinical Trials: Launched the REVERSE-HF prospective, multicenter, randomized controlled trial in December 2021 to compare ultrafiltration to IV diuretics in heart failure patients, with 155 patients enrolled as of February 28, 2025, targeting 372 patients by mid-2026. Data from the ULTRA-PEDs multicenter pediatric registry was presented in March 2025, indicating the Aquadex device's utility in children with end-stage renal disease (ESRD) or acute kidney injury (AKI).
• Product Development: Developing a dedicated Continuous Renal Replacement Therapy (CRRT) device, branded Vivian, for pediatric patients weighing 2.5kg and above, with preliminary engineering testing completed in Q4 2023. An Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration (FDA) is anticipated in Q3 2026, with U.S. commercialization expected in Q2 2028.
• Regulatory & Reimbursement: Received CE Mark Certification for its 24-Hour Blood Circuit Set in January 2022, enabling marketing in the European Union and other recognizing countries. A new Category III Current Procedural Terminology (CPT) code (0692T) for Therapeutic Ultrafiltration became effective January 1, 2022, and was associated with a higher-reimbursement Level II Ambulatory Payment Classification (APC) code for outpatient settings on January 1, 2025.
• Product Recall: In December 2024, Nuwellis, Inc. initiated a voluntary Class 1 recall of specific lots of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit due to "Ultrafiltrate Weight Mismatch" or "Excessive Weight Mismatch" alarms, which could lead to acute volume depletion. Five incidences were reported, with three resulting in patient dehydration.
• Partnerships & Settlements: Terminated a Supply and Collaboration Agreement with DaVita Inc. effective August 21, 2024. Entered into a Confidential Settlement Agreement and Release with SeaStar Medical Holding Corporation on October 20, 2024, terminating prior agreements, which resulted in a $900,000 payment to Nuwellis, Inc. by December 31, 2024.

Geographic Footprint: Nuwellis, Inc. primarily operates in the United States through a direct salesforce. Internationally, it has distribution agreements in several countries across Europe, South America, the Middle East, and Asia, including Austria, Belarus, Brazil, Colombia, Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovak Republic, Spain, Switzerland, Thailand, United Arab Emirates and the United Kingdom. The company also has a wholly owned subsidiary in Ireland.

Financial Performance

Revenue Analysis

Profitability Metrics (2024):

• Gross Margin: 64.9%
• Operating Margin: (125.7)%
• Net Margin: (127.7)%

Investment in Growth:

• R&D Expenditure: $3.2 million (36.7% of revenue)
• Capital Expenditures: $0.1 million
• Strategic Investments: Development of the Vivian pediatric CRRT device (partially funded by a $1.7 million grant from the National Institute of Health), and the REVERSE-HF heart failure clinical study.

Business Segment Analysis

Nuwellis, Inc. operates and manages its business as a single operating segment focused on fluid overload. However, it targets commercial activities across three primary clinical areas:

Heart Failure

Financial Performance:

• Revenue: Approximately 20% of total 2024 revenue.
• Market Opportunity: The total U.S. heart failure market is estimated at approximately $1 billion.
• Key Growth Drivers: High prevalence of heart failure (6.7 million Americans, expected to rise to 8.5 million by 2030), over 1 million annual hospitalizations in the U.S. and Europe due to fluid overload, and potential for reduced hospital readmissions and length of stay with ultrafiltration therapy.

Product Portfolio:

• The Aquadex System is used for inpatient and outpatient care of heart failure patients with fluid overload unresponsive to diuretics.
• Ongoing REVERSE-HF clinical trial to further demonstrate benefits of ultrafiltration versus IV diuretics.

Market Dynamics:

• Heart failure is a leading cause of death and hospitalizations, with significant economic burden ($60.2 billion annually in the U.S.).
• Hospitals face penalties for heart failure readmissions under the Hospital Readmissions Reduction Program.
• Diuretic resistance is common (10-40% of heart failure patients), and poor diuretic response is associated with higher rehospitalization rates.

Critical Care

Financial Performance:

• Revenue: Approximately 40% of total 2024 revenue.
• Market Opportunity: The total U.S. critical care market for fluid overload is estimated at approximately $900 million.
• Key Growth Drivers: Fluid overload in post-cardiac surgery (e.g., CABG, valve repairs), cardiogenic shock, liver and other organ transplants, ventricular assist device (VAD) implants, extracorporeal membrane oxygenation (ECMO) therapy, sepsis, liver disease, and severe burns.

Product Portfolio:

• The Aquadex System is used to manage fluid overload in various critical care settings.
• The company believes it can expand use cases without additional FDA labeling changes.

Market Dynamics:

• Over 7.3 million cardiovascular operations annually in the U.S., with cardiac surgery often leading to fluid overload.
• Fluid overload in post-cardiac surgery is associated with increased operative death, longer hospital stays, and high readmission rates (13.5% within 30 days due to fluid overload).
• New guidelines suggest avoiding loop diuretics in certain cardiac surgery patients.

Pediatrics

Financial Performance:

• Revenue: Approximately 40% of total 2024 revenue.
• Market Opportunity: The total U.S. pediatric market for fluid overload is estimated at approximately $130 million.
• Key Growth Drivers: Fluid overload in pediatric patients due to cardiac surgery, organ transplants, heart failure, and ECMO therapy.
• Product Development: Developing the Vivian CRRT device for neonates and premature infants weighing 2.5kg and above, addressing an unmet medical need for patients with non-functioning kidneys.

Product Portfolio:

• The Aquadex System is FDA cleared for pediatric patients weighing 20 kg or more.
• The Vivian CRRT device is under development for smaller pediatric patients.

Market Dynamics:

• Fluid overload significantly increases pediatric morbidity and mortality risk in critically ill patients (3% increase in mortality for every 1% increase in fluid overload).
• Approximately 10,000 to 14,000 pediatric patients suffer from heart failure, with over 1,800 neonates experiencing AKI.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Nuwellis, Inc. has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain earnings for business development and expansion.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $5.1 million
• Total Debt: $2.9 million (comprising current liabilities and non-current operating lease liability, excluding warrant liability)
• Net Cash Position: $2.2 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Operating lease obligations include $0.3 million due within 1-3 years.

Cash Flow Generation (2024):

• Operating Cash Flow: $(9.6) million
• Free Cash Flow: $(9.7) million (Operating Cash Flow less Capital Expenditures)
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Nuwellis, Inc. manufactures the Aquadex System, including the Aquadex SmartFlow console and blood circuits, at its 23,000 square foot facility in Eden Prairie, Minnesota. The company purchases parts and components from third-party manufacturers and suppliers.

Supply Chain Architecture: Key Suppliers & Partners:

• Nuwellis, Inc. relies on third-party suppliers, including single-source suppliers, for certain components of the Aquadex System. The company does not have long-term contracts with the majority of these suppliers, making it vulnerable to supply problems and price fluctuations.

Facility Network:

• Manufacturing: A 23,000 square foot facility in Eden Prairie, Minnesota, which also serves as the corporate headquarters.
• Research & Development: R&D activities are conducted within the same facility, focusing on Aquadex System improvements and new product development.
• Distribution: Not explicitly detailed beyond direct sales and international distributors.

Operational Metrics: Not disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Nuwellis, Inc. employs a direct salesforce in the United States, comprising 19 full-time sales and marketing employees across 9 sales territories. This team targets healthcare systems and academic hospitals specializing in advanced heart failure and critical care, as well as pediatric hospitals.
• Channel Partners: The company utilizes independent specialty distributors for sales to hospitals and clinics in various international regions, including Europe, South America, the Middle East, and Asia.

Customer Portfolio: Customer Concentration:

• Nuwellis, Inc.'s ten largest customers accounted for 49.4% of its total revenue in 2024 (50.4% in 2023).
• The largest single customer represented 14.4% of total revenue in 2024 (13.9% in 2023), indicating a concentration risk.

Geographic Revenue Distribution:

• The majority of sales are generated in the United States. International sales decreased in 2024. Specific revenue percentages by region are not disclosed.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The fluid overload market is characterized by a high incidence of conditions like heart failure (6.7 million Americans, projected to reach 8.5 million by 2030) and critical care procedures (over 7.3 million cardiovascular operations annually in the U.S.). Fluid overload is a primary reason for over 1 million heart failure hospitalizations annually in the U.S. and Europe, and a significant driver of pediatric morbidity and mortality. The market faces challenges with traditional diuretic therapies, including resistance and associated kidney damage.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Diuretics: Pharmacological treatment remains the standard of care for fluid overload. Nuwellis, Inc. competes by demonstrating the advantages of ultrafiltration over diuretics, especially for diuretic-resistant patients.

Indirect Competitors:

• Baxter’s Prismaflex: A filter-based device approved for continuous renal replacement therapy (CRRT) in patients weighing 20kg or more with acute renal failure and/or fluid overload, but with significant limitations for ultrafiltration.
• Medtronic's Carpediem system: Indicated for acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy in pediatrics.
• Baxter’s HF20 Set: Authorized under an Emergency Use Authorization for CRRT in low-weight pediatric patients (8-20kg) during the COVID-19 pandemic.

Emerging Competitive Threats:

• Mozarc Medical (Medtronic and DaVita Inc. joint venture): Formed to pursue various kidney applications, potentially increasing competition in Nuwellis, Inc.'s customer categories.

Competitive Response Strategy: Nuwellis, Inc. aims to maintain its competitive advantage by demonstrating the clinical and economic benefits of ultrafiltration compared to diuretics, differentiating the Aquadex System from other devices capable of ultrafiltration, and expanding its use cases in critical care and pediatrics.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Single Product Dependence: Near-term prospects are highly dependent on revenues from the Aquadex System, with no other commercial products currently available. Expanding market acceptance faces significant challenges.
• Technology Disruption: Intense and increasing competition from medical device companies, pharmaceutical companies, and gene- and cell-based therapies.

Customer Concentration:

• Dependency Risks: The ten largest customers represented 49.4% of 2024 revenues, with the largest customer accounting for 14.4%. Loss of a major customer or reduced purchases could materially adversely affect revenue.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on third-party suppliers, including single-source suppliers, for certain Aquadex System components. Lack of long-term contracts with most suppliers creates vulnerability to supply problems and price fluctuations.
• Capacity Constraints: Limited commercial manufacturing experience could lead to difficulties in producing commercial volumes of the Aquadex System and related components.
• Product Defects: A voluntary Class 1 recall of specific blood circuit lots in December 2024 due to malfunction alarms highlights product liability risks, with reported incidences of patient dehydration.

Financial & Regulatory Risks

Market & Financial Risks:

• Liquidity & Going Concern: Nuwellis, Inc. has incurred operating losses since inception (accumulated deficit of $298.8 million as of December 31, 2024) and expects to continue incurring losses. Additional capital is required to fund operations through the end of fiscal year 2025, raising substantial doubt about the company's ability to continue as a going concern.
• Nasdaq Delisting: The company has faced non-compliance with Nasdaq's minimum bid price and stockholders' equity requirements, leading to a Mandatory Panel Monitor for one year from December 17, 2024. Delisting could adversely affect capital raising and stock liquidity.

Regulatory & Compliance Risks:

• Industry Regulation: Subject to rigorous FDA regulations (FDC Act, 510(k) clearance, QSR, GMP, MDRs) and European Union regulations (Medical Devices Directive, MDR 2017/745, CE Mark). Non-compliance could lead to enforcement actions, delays, or market withdrawal.
• Healthcare Reform: Uncertainty regarding government healthcare reform and changes to healthcare regulations (e.g., Affordable Care Act, Hospital Readmissions Reduction Program) could negatively impact payment rates and business operations.
• Fraud and Abuse Laws: Subject to federal and state fraud and abuse laws (Anti-Kickback Statute, Stark law, False Claims Act), with potential for substantial penalties for non-compliance.

Geopolitical & External Risks

Geographic Dependencies:

• International Operations: International operations are subject to risks including foreign exchange rate fluctuations, difficulties in enforcing receivables, political instability, longer payment cycles, and potential imposition of additional taxes or import restrictions.
• Trade Relations: Changes to U.S. tariff and import/export regulations could negatively impact supplier costs and financial condition.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Aquadex System Enhancements: Ongoing project to enhance the functionality of the hematocrit sensor integrated into the Aquadex console, expected to be completed in 2025.
• Pediatric CRRT Device: Development of the Vivian CRRT device, a dedicated system for pediatric patients weighing 2.5kg and above who require kidney replacement therapy.

Innovation Pipeline:

• Hematocrit Sensor Enhancement: Expected completion in 2025.
• Vivian Pediatric CRRT Device: Preliminary engineering testing completed in Q4 2023. IDE submission to the FDA is planned for Q3 2026, with U.S. commercialization anticipated in Q2 2028.

Intellectual Property Portfolio:

• Patent Strategy: Nuwellis, Inc. has submitted patent applications to build its intellectual property portfolio. It holds ten company-owned patents, including two issued within the last two years. Additionally, it has four pending U.S. patent applications unrelated to its dedicated pediatric device and a family of patent applications for the pediatric device, which has resulted in four issued U.S. patents, five pending U.S. patent applications, and one pending international patent application.
• Licensing Programs: Holds a patent license agreement with Baxter for patents used in connection with the Aquadex System, with the last licensed patent estimated to expire by mid-2025.
• IP Litigation: Nuwellis, Inc. is not currently a party to any legal proceedings related to patents or intellectual property rights.

Technology Partnerships:

• Research Collaborations: The development of the Vivian pediatric CRRT device is funded in part by a $1.7 million grant from the National Institute of Health.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Nestor Jaramillo, Jr., the former President and Chief Executive Officer, retired on February 23, 2025, and John L. Erb was appointed as Interim President and Chief Executive Officer.

Board Composition: The Board of Directors consists of six members serving staggered three-year terms. Five directors (Dr. Maria Rosa Costanzo, Dr. Archelle Georgiou, Mr. Michael McCormick, Mr. David McDonald, and Mr. Gregory D. Waller) are independent under Nasdaq rules. Mr. John L. Erb serves as Chairman of the Board and Interim CEO. Mr. Michael McCormick serves as the lead independent director. The Audit Committee comprises Mr. Michael McCormick, Mr. David McDonald, and Mr. Gregory D. Waller, with Mr. Waller qualifying as an "audit committee financial expert."

Human Capital Strategy

Workforce Composition:

• Total Employees: 38 full-time employees as of December 31, 2024.
• Geographic Distribution: Not disclosed, but operations are in the U.S. and Ireland.
• Skill Mix: Not disclosed.

Talent Management: Acquisition & Retention:

• Nuwellis, Inc. has various share-based compensation plans (2017 Equity Incentive Plan, 2021 Inducement Plan) designed to attract, motivate, and retain employees and directors.
• The company implemented efficiency initiatives in late 2023 and early 2024, including reductions in senior management salaries, temporary suspension of 401(k) match (restored October 1, 2024), and reductions in travel and professional services, to manage cash burn.

Diversity & Development:

• Diversity Metrics: Not disclosed.
• Development Programs: Not disclosed.
• Culture & Engagement: Not disclosed.

Environmental & Social Impact

Environmental Commitments:

• Climate Strategy: Nuwellis, Inc. is evaluating the impact of new SEC rules (effective for non-accelerated filers January 1, 2027) requiring disclosure of material Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics. Specific emissions targets or carbon neutrality commitments are not disclosed.
• Renewable Energy: Not disclosed.

Supply Chain Sustainability:

• Supplier Engagement: Not disclosed.
• Responsible Sourcing: Not disclosed.

Social Impact Initiatives:

• Community Investment: Not disclosed.
• Product Impact: Not disclosed.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Customer ordering patterns for the Aquadex System may vary significantly from quarter to quarter.
• Economic Sensitivity: Worldwide economic and market conditions, including inflation, interest rate increases, and geopolitical events, could adversely affect business, results of operations, liquidity, and stock price.

Planning & Forecasting:

• Demand forecasting approach, inventory management, and capacity planning are not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• United States: Nuwellis, Inc. is subject to the Federal Food, Drug, and Cosmetic Act (FDC Act) and FDA regulations governing medical device design, development, testing, premarket clearance (510(k)), manufacturing (Quality System Regulation - QSR, Good Manufacturing Practices - GMP), labeling, promotion, and post-market surveillance (Medical Device Reports - MDRs).
• European Union: Products must comply with the essential requirements of the European Union Medical Devices Directive (Council Directive 93/42/EEC) and the new EU Medical Device Regulation 2017/745 (MDR) to affix the CE Mark. Nuwellis, Inc. is in the process of obtaining MDR certification with its Notified Body, GMED, with the transition period extended to December 31, 2028.

Trade & Export Controls:

• Export Restrictions: Not explicitly detailed beyond general risk factors.
• Sanctions Compliance: Not explicitly detailed beyond general risk factors.

Legal Proceedings:

• Nuwellis, Inc. is not currently subject to any legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Nuwellis, Inc. has not recognized any income tax benefit related to its U.S. operating losses, as all tax benefits are fully reserved. Minimal income tax expense is generated from its Irish subsidiary.
• Geographic Tax Planning: The company's international tax structure and transfer pricing are not explicitly detailed.
• Tax Reform Impact: As of December 31, 2024, Nuwellis, Inc. had federal net operating loss (NOL) carryforwards of approximately $220.2 million ($119.2 million expiring between 2025 and 2038, and $101.0 million generated after 2017 with no expiration). State NOL carryforwards totaled $66.2 million. The company believes it has experienced ownership changes under Section 382 of the Internal Revenue Code, which will limit the utilization of these NOLs.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Nuwellis, Inc. carries product liability insurance with a $6.0 million aggregate limit.
• Risk Transfer Mechanisms: Not explicitly detailed.